Comparative Pharmacology
Head-to-head clinical analysis: CAPTOPRIL AND HYDROCHLOROTHIAZIDE versus ESIDRIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPTOPRIL AND HYDROCHLOROTHIAZIDE versus ESIDRIX.
CAPTOPRIL AND HYDROCHLOROTHIAZIDE vs ESIDRIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, resulting in vasodilation and decreased aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.
1 tablet (captopril 25 mg / hydrochlorothiazide 15 mg) orally once daily, titrated up to a maximum of 1 tablet (captopril 50 mg / hydrochlorothiazide 25 mg) twice daily.
25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.
None Documented
None Documented
Captopril: ~2 hours (prolonged to 6-8 hours in heart failure or renal impairment). Hydrochlorothiazide: 5.6-14.8 hours (mean ~9.6 hours; prolonged in renal impairment).
Terminal elimination half-life is approximately 10-15 hours (mean 12 hours); clinical context: half-life prolonged in renal impairment, requiring dose adjustment.
Captopril: renal (95%), primarily as unchanged drug and disulfide metabolites. Hydrochlorothiazide: renal (≥95%) as unchanged drug via tubular secretion.
Renal: approximately 70% excreted unchanged in urine; biliary/fecal: less than 10%.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic